289 related articles for article (PubMed ID: 21134982)
1. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Della Porta MG; Malcovati L; Strupp C; Ambaglio I; Kuendgen A; Zipperer E; Travaglino E; Invernizzi R; Pascutto C; Lazzarino M; Germing U; Cazzola M
Haematologica; 2011 Mar; 96(3):441-9. PubMed ID: 21134982
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
Breccia M; Federico V; Latagliata R; Mercanti C; D'Elia GM; Cannella L; Loglisci G; Salaroli A; Santopietro M; Alimena G
Leuk Res; 2011 Feb; 35(2):159-62. PubMed ID: 20594593
[TBL] [Abstract][Full Text] [Related]
3. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
4. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS).
Malcovati L; Della Porta MG; Strupp C; Ambaglio I; Kuendgen A; Nachtkamp K; Travaglino E; Invernizzi R; Pascutto C; Lazzarino M; Germing U; Cazzola M
Haematologica; 2011 Oct; 96(10):1433-40. PubMed ID: 21659359
[TBL] [Abstract][Full Text] [Related]
5. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.
Malcovati L; Germing U; Kuendgen A; Della Porta MG; Pascutto C; Invernizzi R; Giagounidis A; Hildebrandt B; Bernasconi P; Knipp S; Strupp C; Lazzarino M; Aul C; Cazzola M
J Clin Oncol; 2007 Aug; 25(23):3503-10. PubMed ID: 17687155
[TBL] [Abstract][Full Text] [Related]
6. Classification and prognostic evaluation of myelodysplastic syndromes.
Cazzola M; Della Porta MG; Travaglino E; Malcovati L
Semin Oncol; 2011 Oct; 38(5):627-34. PubMed ID: 21943669
[TBL] [Abstract][Full Text] [Related]
7. The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromes.
Castelli R; Schiavon R; Deliliers GL
Med Oncol; 2018 Feb; 35(3):33. PubMed ID: 29417235
[TBL] [Abstract][Full Text] [Related]
8. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.
Zipperer E; Pelz D; Nachtkamp K; Kuendgen A; Strupp C; Gattermann N; Haas R; Germing U
Haematologica; 2009 May; 94(5):729-32. PubMed ID: 19336740
[TBL] [Abstract][Full Text] [Related]
9. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
Balleari E; Salvetti C; Del Corso L; Filiberti R; Bacigalupo A; Bellodi A; Beltrami G; Bergamaschi M; Berisso G; Calzamiglia T; Carella AM; Cavalleri M; Da Col A; Favorini S; Forni GL; Goretti R; Miglino M; Mitscheuning L; Molinari E; Racchi O; Scudeletti M; Tassara R; Gobbi M; Lemoli R; Clavio M
Leuk Res; 2015 Aug; 39(8):846-52. PubMed ID: 26145790
[TBL] [Abstract][Full Text] [Related]
10. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
Naqvi K; Garcia-Manero G; Sardesai S; Oh J; Vigil CE; Pierce S; Lei X; Shan J; Kantarjian HM; Suarez-Almazor ME
J Clin Oncol; 2011 Jun; 29(16):2240-6. PubMed ID: 21537048
[TBL] [Abstract][Full Text] [Related]
11. Combination of Frailty Status and Comorbidity Score Improves the Stratification of Survival in Patients With Myelodysplastic Syndrome Owing to Good Predictive Capability for Infection-related Mortality.
Sakatoku K; Takeoka Y; Miura A; Araki T; Fujitani Y; Yamamura R; Nakamae H; Ohta K; Hino M
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):799-805. PubMed ID: 31648956
[TBL] [Abstract][Full Text] [Related]
12. The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome.
Falantes JF; Márquez-Malaver FJ; Knight T; Calderón-Cabrera C; Martino ML; González J; Montero I; Espigado I; Pérez-Simón JA
Leuk Lymphoma; 2017 Aug; 58(8):1893-1902. PubMed ID: 27951729
[TBL] [Abstract][Full Text] [Related]
13. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.
Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Br J Haematol; 2018 Jun; 181(5):614-627. PubMed ID: 29707769
[TBL] [Abstract][Full Text] [Related]
14. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes.
Wang R; Gross CP; Halene S; Ma X
Leuk Res; 2009 Dec; 33(12):1594-8. PubMed ID: 19324411
[TBL] [Abstract][Full Text] [Related]
15. Prognostic classification and risk assessment in myelodysplastic syndromes.
Cazzola M; Malcovati L
Hematol Oncol Clin North Am; 2010 Apr; 24(2):459-68. PubMed ID: 20359637
[TBL] [Abstract][Full Text] [Related]
16. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I
Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951
[TBL] [Abstract][Full Text] [Related]
17. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.
Hiwase DK; Singhal D; Strupp C; Chhetri R; Kutyna MM; Wee LA; Harrison PB; Nath SV; Wickham N; Hui CH; Gray JX; Bardy P; Ross DM; Lewis ID; Reynolds J; To LB; Germing U
Am J Hematol; 2017 Jun; 92(6):508-514. PubMed ID: 28247421
[TBL] [Abstract][Full Text] [Related]
18. The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.
Zipperer E; Tanha N; Strupp C; Kündgen A; Nachtkamp K; Neukirchen J; Hildebrandt B; Haas R; Gattermann N; Germing U
Haematologica; 2014 Mar; 99(3):e31-2. PubMed ID: 24463211
[No Abstract] [Full Text] [Related]
19. Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome.
Della Porta MG; Malcovati L
Haematologica; 2009 May; 94(5):602-6. PubMed ID: 19407314
[TBL] [Abstract][Full Text] [Related]
20. Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities.
Sevindik OG; Guc Z; Kahraman S; Medeni Solmaz S; Katgi A; Acar C; Alacacioglu I; Piskin O; Ozsan GH; Demirkan F; Undar B; Ozcan MA
Leuk Lymphoma; 2015; 56(9):2552-5. PubMed ID: 25669924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
